TakahashT.Reconsidering cancer screening, cancer-specific mortality, and overdiagnosis: a public health and ethical perspective. Med Decis Making. 2026;46(2):125–127. DOI: 10.1177/0272989X251401195
2.
HenningCSroczynskiGHallssonLJahnBSiebertUMühlbergerN.Life expectancy predicted by decision-analytic models evaluating screening for prostate, lung, breast, and colorectal cancer: a systematic review focusing on competing mortality risks. Med Decis Making. 2025;45(8):927–50.
OwensDKWhitlockEPHendersonJ, et al. Use of decision models in the development of evidence-based clinical preventive services recommendations: methods of the U.S. preventive services task force. Ann Intern Med. 2016;165(7):501–8.
5.
GartlehnerGSchernhammerELaxSF, et al. Screening for colorectal cancer: a recommendation statement of the Austrian National Committee for Cancer Screening. Wien Klin Wochenschr. 2023;135(17–18):447–55.
6.
SiebertU.Using decision-analytic modelling to transfer international evidence from health technology assessment to the context of the German health care system. GMS Health Technol Assess. 2005;1:Doc03.
7.
SiebertU.When should decision-analytic modeling be used in the economic evaluation of health care? [Editorial]. Eur J Health Econ. 2003;4(3):143–50.
8.
SroczynskiGHallsson LáraRMühlbergerN, et al. Including decision-analytic benefit-harm evaluation in HTA—different age ranges and screening intervals in breast cancer screening in Germany [Poster presentation]. ISPOR Europe, 2022; Vienna, Austria.
